LBF

Lynparza is now the primary PARP inhibitor to claim a win that, as ASCO put it, “could change the standard of care in adjuvant systemic therapy” for germline BRCA1/2-mutated, HER2-adverse early breast cancer. With the primary and solely accredited focused alpha remedy Xofigo, Bayer has successfully established Xofigo as a TAT for males with mCRPC, symptomatic bone metastases and no known visceral metastases. Adding actinium-225-labeled small molecule to the company’s platform of investigational focused thorium conjugates, supports our commitment to researching differentiated treatment options for cancer patients. Doctors are reporting improved survival in men with extensively spread prostate cancer from …